Eduovisual
Cardiovascular
Atrial fibrillation: rate vs rhythm control strategy
— Prevalence rises sharply with age: ~1% at age 60, >10% by age 80.
— Major driver of ischemic stroke (~15–20% of all strokes), heart failure exacerbations, and hospital readmissions.
— Lifetime risk ~1 in 3 for adults of European ancestry; rising in all populations with obesity and OSA.
— Paroxysmal: terminates within 7 days (often <24h), spontaneously or with intervention.
— Persistent: >7 days, requires cardioversion to terminate.
— Long-standing persistent: continuous >12 months but rhythm control still considered.
— Permanent: joint clinician/patient decision to abandon rhythm control.
— Palpitations, fatigue, exertional dyspnea, lightheadedness, decreased exercise tolerance, or syncope.
— Asymptomatic in up to one-third — discovered on routine exam, preop ECG, wearable device, or after embolic stroke ("AF detected after stroke").
— Acute decompensation in HF, new ischemic stroke, or unexplained heart rate >100 in an older adult.
— HTN (most common), HF, valvular disease (especially mitral), CAD, hyperthyroidism, obesity, OSA, alcohol ("holiday heart"), CKD, post-cardiac surgery, sepsis, PE.
Board pearl: Step 3 vignettes frequently embed AF discovery in an ambulatory follow-up visit (e.g., post-hospitalization for pneumonia, 2-week wearable strip) — your first move is not to pick rate vs rhythm but to document AF on a 12-lead ECG, assess hemodynamics, and calculate CHA₂DS₂-VASc for stroke prevention, which is independent of the rate/rhythm decision.
— Mild/intermittent: palpitations, "fluttering," fatigue, decreased exercise tolerance, mild dyspnea — typical of paroxysmal AF in younger patients.
— Moderate: new-onset dyspnea, orthopnea, lower extremity edema (rate-related cardiomyopathy or unmasked HFpEF).
— Severe: angina from demand ischemia, presyncope/syncope, acute pulmonary edema, hypotension, embolic stroke as first presentation.
— Onset and duration: "Did symptoms start <48 hours ago?" drives cardioversion safety.
— Pattern: episodic vs persistent — guides paroxysmal vs persistent classification.
— Triggers: binge alcohol (holiday heart), stimulants (caffeine, decongestants, cocaine, methamphetamine), recent thoracic surgery, acute illness (sepsis, PE, MI, hyperthyroidism).
— Prior episodes and prior therapy: previous cardioversions, antiarrhythmics tried, ablation history.
— Bleeding history: GI bleed, intracranial hemorrhage, falls — critical for anticoagulation decisions.
— Functional status and quality-of-life impact: drives rhythm-control bias.
— Hypertension, diabetes, CAD, HF (with EF if known), CKD, prior stroke/TIA, vascular disease, OSA (loud snoring, witnessed apneas, daytime somnolence), hyperthyroidism (weight loss, heat intolerance), heavy alcohol use.
— QT-prolonging drugs (limit antiarrhythmic choices), beta-blocker or CCB intolerance, warfarin interactions, prior bleeding on DOAC.
Step 3 management: When a patient presents to clinic with palpitations and an irregular pulse, order a 12-lead ECG immediately; if not captured, escalate to ambulatory monitoring — 24–48h Holter for daily symptoms, 14–30 day event monitor for weekly symptoms, or implantable loop recorder for cryptogenic stroke workup. Duration of monitoring is matched to symptom frequency — this matching is a classic Step 3 testable point.
— Irregularly irregular pulse — the defining bedside finding; no pattern to the irregularity (distinguishes from frequent PACs/PVCs or 2:1 AV block).
— Variable S1 intensity due to changing diastolic filling times.
— Pulse deficit: apical heart rate > radial rate because weak beats fail to generate a palpable pulse — a useful clue when rapid.
— Absent a waves in jugular venous pulsations (no organized atrial contraction).
— Stable: normotensive, mentating well, no chest pain, no pulmonary edema → time for workup and decision between rate vs rhythm.
— Unstable: hypotension (SBP <90 or signs of shock), altered mental status, ischemic chest pain, acute pulmonary edema → immediate synchronized DC cardioversion regardless of duration or anticoagulation status (post-shock anticoagulation still required).
— Heart failure: elevated JVP, S3, crackles, peripheral edema, hepatojugular reflux.
— Valvular disease: mid-diastolic rumble (mitral stenosis — classic AF substrate), holosystolic murmur (MR), systolic ejection murmur (AS).
— Hyperthyroidism: tremor, lid lag, warm moist skin, goiter, brisk reflexes.
— PE: tachypnea, hypoxia, unilateral leg swelling, pleuritic chest pain.
— Sepsis: fever, warm extremities, hypotension responsive to fluids.
— Focal deficits suggest embolic stroke as the presentation; this changes timing of cardioversion and initiation of anticoagulation.
CCS pearl: On the CCS case, the very first orders after recognizing AF with RVR should be IV access, continuous cardiac monitoring, pulse oximetry, 12-lead ECG, and vitals q15min. If the patient is unstable, synchronized cardioversion at 120–200 J biphasic is the next order — do not wait for TEE or anticoagulation labs.
— Absent P waves, replaced by fibrillatory (f) waves of varying amplitude.
— Irregularly irregular R-R intervals.
— Narrow QRS unless aberrancy, preexisting BBB, or accessory pathway conduction.
— Look for clues to substrate: LVH (HTN), Q waves (prior MI), delta wave (WPW — critical, changes drug choice), prolonged QT (limits sotalol/dofetilide), pre-excitation.
— CBC (anemia worsens symptoms and complicates anticoagulation).
— BMP — potassium and magnesium (low levels predispose to arrhythmia and prolong QT; replete to K ≥4.0, Mg ≥2.0).
— TSH — hyperthyroidism is a reversible cause; never miss this on Step 3.
— LFTs — baseline before amiodarone or DOACs.
— Coagulation studies (PT/INR, aPTT) and CrCl — critical for anticoagulant dosing.
— Troponin if chest pain, hypotension, or HF — demand ischemia is common with RVR.
— BNP/NT-proBNP if HF suspected.
— Chest X-ray: pulmonary edema, cardiomegaly, infiltrate suggesting precipitant.
— Transthoracic echocardiogram (TTE) — obtain in all newly diagnosed AF to assess LA size, LV function (EF), valvular disease, pericardial effusion, and right heart strain.
— D-dimer/CT-PA if PE is in the differential (PE precipitates AF in up to 5% of new-onset cases).
Key distinction: Atrial flutter has organized sawtooth flutter waves (best in inferior leads) and typically a regular ventricular response at 150 bpm (2:1 block). It shares thromboembolic risk with AF — apply the same CHA₂DS₂-VASc-based anticoagulation rule — but flutter is more amenable to cavotricuspid isthmus ablation as definitive rhythm control.
— Gold standard to exclude left atrial appendage (LAA) thrombus.
— Indicated when early cardioversion is desired but AF duration is ≥48 hours or unknown and the patient has not had ≥3 weeks of therapeutic anticoagulation.
— A negative TEE permits immediate cardioversion followed by ≥4 weeks of anticoagulation (atrial stunning persists post-cardioversion regardless of rhythm restoration).
— Holter (24–48 h): daily symptoms or rate-control assessment.
— Event monitor (14–30 days): weekly symptoms, paroxysmal AF burden quantification.
— Implantable loop recorder (up to 3 years): cryptogenic stroke workup or rare symptoms — CRYSTAL-AF trial supports.
— Consumer wearables (Apple Watch, Kardia): screening tool; always confirm with a 12-lead ECG before treating.
— Assess rate control during exertion (resting rate may look fine but be uncontrolled with activity).
— Screen for ischemia before initiating flecainide or propafenone (Class IC drugs contraindicated in CAD/structural heart disease per CAST trial logic).
— Used selectively for atrial fibrosis quantification (DECAAF data), assessment of cardiomyopathy substrate, or when echo is suboptimal.
— Polysomnography for suspected OSA — untreated OSA dramatically reduces success of rhythm control and ablation.
— Used during ablation procedures; not a routine diagnostic test.
Board pearl: A patient with AF for unknown duration who is hemodynamically stable and wants rhythm control has two acceptable pathways: (1) 3 weeks of therapeutic anticoagulation → cardioversion → 4 weeks post-cardioversion anticoagulation, or (2) TEE-guided immediate cardioversion with anticoagulation initiated before the procedure and continued ≥4 weeks after. Either way, long-term anticoagulation depends on CHA₂DS₂-VASc, not on the success of cardioversion.
— 1. Stroke prevention (anticoagulation based on CHA₂DS₂-VASc).
— 2. Rate vs rhythm control strategy.
— 3. Treatment of underlying drivers (HTN, OSA, obesity, alcohol, thyroid).
— CHF (1), HTN (1), Age ≥75 (2), DM (1), prior Stroke/TIA/thromboembolism (2), Vascular disease (1), Age 65–74 (1), Sex category female (1, only counts when ≥1 other risk factor).
— Men ≥2, women ≥3: anticoagulate.
— Men =1, women =2: consider anticoagulation (2023 AHA/ACC favors offering it).
— Score 0 (men) or 1 (women): no anticoagulation needed.
— Rate control is acceptable first-line for most older, minimally symptomatic patients (AFFIRM, RACE trials showed no mortality difference vs rhythm control).
— Rhythm control favored in:
— Younger patients, first episode, highly symptomatic, HF with reduced EF (CASTLE-AF, EAST-AFNET 4 favor early rhythm control), tachycardia-mediated cardiomyopathy, failed rate control, professional/athletic activity.
— EAST-AFNET 4 (2020): early rhythm control (within 1 year of diagnosis) reduced CV death, stroke, and HF hospitalization vs usual care.
Step 3 management: When the vignette features a 70-year-old with AF, hypertension, and minimal symptoms, the correct answer is usually rate control + anticoagulation. When it features a 55-year-old with new AF, EF 30%, and dyspnea, the answer shifts toward early rhythm control (cardioversion ± antiarrhythmic, with ablation referral). Match strategy to age, EF, and symptom burden.
— Beta-blockers (first-line): metoprolol tartrate 25–100 mg BID or IV 5 mg q5min × 3; carvedilol or bisoprolol if HFrEF. Preferred in CAD, post-MI, HF.
— Non-dihydropyridine CCBs: diltiazem 0.25 mg/kg IV bolus then 5–15 mg/h drip; oral 120–360 mg/day. Avoid in HFrEF (negative inotropy worsens decompensation).
— Digoxin: add-on agent, especially in sedentary patients or HFrEF; less effective with exertion; narrow therapeutic window — toxicity in CKD/elderly.
— Amiodarone: rate control only when others fail or contraindicated; risks of conversion to sinus (embolic if not anticoagulated).
— No structural heart disease: flecainide or propafenone (Class IC) — preferred; "pill-in-pocket" option for paroxysmal AF in selected patients (must be paired with AV nodal blocker to prevent 1:1 flutter conduction).
— CAD or LVH ≥1.5 cm: sotalol (Class III; monitor QT, requires inpatient initiation; renal dosing) or dofetilide (mandatory 3-day inpatient telemetry initiation, strict CrCl-based dosing).
— HFrEF: amiodarone (most effective, but pulmonary, hepatic, thyroid, ocular, skin toxicities) or dofetilide. Avoid dronedarone in NYHA III–IV HF (ANDROMEDA — increased mortality).
— Dronedarone: for paroxysmal AF without HF; less effective than amiodarone but safer side-effect profile.
— Electrical (DC): 120–200 J biphasic synchronized; success ~90%.
— Pharmacologic: ibutilide (acute), flecainide/propafenone PO (outpatient pill-in-pocket).
Board pearl: Flecainide and propafenone are contraindicated in CAD, prior MI, and structural heart disease (CAST trial — increased mortality). If the vignette mentions any of these, switch to sotalol, dofetilide, or amiodarone. This is one of the most repeatedly tested AF pharmacology distinctions on Step 3.
— Emergent: unstable AF — synchronized 120–200 J biphasic, no anticoagulation prerequisite.
— Elective: stable AF — requires either ≥3 weeks of therapeutic anticoagulation or TEE excluding LAA thrombus.
— Post-cardioversion: ≥4 weeks of anticoagulation regardless of CHA₂DS₂-VASc (atrial stunning → thrombus risk); continue long-term if CHA₂DS₂-VASc indicates.
— Indications: symptomatic paroxysmal or persistent AF refractory or intolerant to ≥1 antiarrhythmic; first-line option in selected patients (2023 AHA/ACC Class 1 for symptomatic paroxysmal AF).
— Strongest data: CASTLE-AF — ablation in HFrEF + AF reduced mortality and HF hospitalization. CABANA — ablation improved QoL and reduced AF recurrence.
— Techniques: radiofrequency or cryoballoon PVI; ~70–80% single-procedure success in paroxysmal AF, lower in persistent AF.
— Complications: cardiac tamponade (~1%), atrioesophageal fistula (rare, often fatal — fever + dysphagia + neuro symptoms 1–4 weeks post-ablation), pulmonary vein stenosis, stroke, phrenic nerve injury.
— Performed concomitantly with cardiac surgery (CABG, valve); creates scar lines blocking reentry. Most effective rhythm control intervention.
— Watchman device — alternative to long-term anticoagulation in patients with high stroke risk but contraindication to long-term anticoagulation (recurrent GI bleeding, intracranial hemorrhage, high fall risk per shared decision-making).
— Requires short-term post-implant anticoagulation/DAPT bridge.
CCS pearl: After successful elective cardioversion, your standing orders should include continued anticoagulation × 4 weeks minimum, telemetry observation for 1–2 hours, discharge instructions, and follow-up in 1–2 weeks to assess rhythm maintenance and antiarrhythmic tolerance. Forgetting post-cardioversion anticoagulation is a classic CCS deduction.
— Highest stroke risk — age ≥75 alone contributes 2 points to CHA₂DS₂-VASc.
— Anticoagulation: DOACs preferred over warfarin (ELDERCARE-AF — low-dose edoxaban 15 mg daily reduces stroke in very elderly with bleeding risk vs placebo).
— Rate over rhythm bias: AFFIRM subgroup — no survival benefit from rhythm control in older patients; rhythm-control drugs poorly tolerated.
— Falls: history of falls is NOT a contraindication to anticoagulation — modeling shows ~295 falls/year needed to offset stroke prevention benefit.
— Avoid digoxin when possible (narrow therapeutic index, renal accumulation, increased mortality signal in TREAT-AF).
— CrCl 15–50: dose-adjust DOACs.
— Apixaban 2.5 mg BID if two of three: age ≥80, weight ≤60 kg, Cr ≥1.5.
— Rivaroxaban 15 mg daily if CrCl 15–50.
— Dabigatran 75 mg BID if CrCl 15–30 (avoid <15).
— Edoxaban 30 mg daily if CrCl 15–50; avoid if CrCl >95 (paradoxically less effective).
— CrCl <15 / dialysis: warfarin is the historical default; apixaban increasingly used (AXADIA, RENAL-AF data emerging).
— Sotalol and dofetilide: strict renal dosing; avoid sotalol if CrCl <40; dofetilide requires inpatient initiation with creatinine and QT-based dosing nomogram.
— Child-Pugh B: use rivaroxaban with caution; apixaban/edoxaban acceptable.
— Child-Pugh C: avoid all DOACs; warfarin with caution and close INR monitoring.
— Amiodarone hepatotoxic — check LFTs every 6 months.
Board pearl: The classic Step 3 anticoagulation question features an 82-year-old, Cr 1.6, weight 55 kg with AF — the answer is apixaban 2.5 mg BID (meets two of three dose-reduction criteria). Memorize this triad.
— AF in pregnancy is uncommon; usually in women with structural heart disease (mitral stenosis, congenital heart disease, peripartum cardiomyopathy).
— Anticoagulation: DOACs are contraindicated (cross placenta, limited safety data). Warfarin teratogenic in T1 (especially weeks 6–12) — embryopathy. LMWH preferred throughout pregnancy with anti-Xa monitoring; unfractionated heparin near delivery.
— Rate control: metoprolol or propranolol preferred; avoid atenolol (associated with IUGR).
— Rhythm control: electrical cardioversion is safe in pregnancy (no significant fetal harm). Flecainide acceptable in structurally normal hearts; amiodarone avoided (fetal hypothyroidism, neurodevelopmental concerns).
— Treat the underlying thyroid disease — AF often resolves once euthyroid.
— Rate control with beta-blockers (propranolol — additional benefit of blocking T4→T3 peripheral conversion).
— Anticoagulate during AF even if score is low when actively thyrotoxic — embolic risk is elevated.
— Endurance athletes have increased AF risk (vagal tone, atrial remodeling).
— Pill-in-pocket flecainide/propafenone can permit return to sport.
— Ablation is increasingly first-line in this group.
— Wide, irregular, rapid tachycardia at rates >250 bpm with varying QRS width = AF with pre-excitation.
— AVOID AV nodal blockers (adenosine, beta-blockers, diltiazem, verapamil, digoxin) — they preferentially block AV node and force conduction down the accessory pathway → VF risk.
— Treatment: procainamide or ibutilide IV, or synchronized DCCV if unstable.
Key distinction: Any irregularly irregular wide-complex tachycardia at rates approaching 300 bpm is AF + WPW until proven otherwise — the management pivot away from typical AV nodal blockade is one of the most testable safety points across Steps 2 and 3.
— Ischemic stroke — 4–5× baseline risk; LAA is source of >90% of cardiac thrombi.
— Systemic embolism — mesenteric, renal, splenic, limb ischemia.
— Stroke risk is independent of AF burden in many patients — even paroxysmal AF confers risk (treat per CHA₂DS₂-VASc regardless of pattern).
— Persistent uncontrolled ventricular rates (often >110–120 bpm sustained) → reversible LV dysfunction.
— Rhythm control or aggressive rate control typically reverses EF over weeks to months.
— Consider this in any AF patient with newly reduced EF and no clear ischemic substrate.
— Loss of atrial kick reduces CO by ~20%, more in stiff ventricles (HFpEF, HCM, severe LVH, restrictive cardiomyopathy).
— Major bleeding 2–3%/year on DOACs; GI bleeding more common with rivaroxaban and dabigatran than apixaban.
— Intracranial hemorrhage — less common with DOACs than warfarin (key DOAC advantage).
— Reversal: idarucizumab for dabigatran; andexanet alfa for apixaban/rivaroxaban; 4-factor PCC if specific agents unavailable; vitamin K + PCC for warfarin.
— Amiodarone: pulmonary fibrosis (deadliest), hepatotoxicity, hypo/hyperthyroidism, corneal microdeposits, blue-gray skin, photosensitivity, neuropathy.
— Dronedarone: hepatic failure, increased mortality in HF.
— Digoxin: yellow vision, nausea, AV block, hyperkalemia in acute toxicity — treat with digoxin immune Fab.
Step 3 management: A patient on amiodarone requires TSH and LFTs every 6 months, CXR and PFTs annually (or at symptom onset), and ophthalmologic exam annually. Missing this monitoring schedule is a frequent Step 3 deduction in long-term management questions.
— Hemodynamic instability: hypotension, shock, altered mental status, ischemic chest pain, acute pulmonary edema → synchronized cardioversion now, ICU admission.
— AF with WPW pre-excitation — telemetry/ICU, avoid AV nodal blockers, urgent EP consult.
— New AF with rapid response in the setting of acute MI, PE, sepsis, or thyroid storm — treat the underlying condition in parallel.
— Initiation of dofetilide or sotalol — requires inpatient telemetry monitoring (typically 3 days for dofetilide) for QT and proarrhythmia surveillance.
— RVR refractory to oral rate control in the ED.
— New AF with HF exacerbation requiring diuresis.
— Post-cardioversion observation in select patients.
— Initiation of certain antiarrhythmics requiring monitored loading.
— Hemodynamically stable, controllable rate, no acute precipitant requiring admission.
— Established anticoagulation plan and follow-up in place.
— Patient understands red-flag symptoms.
— Recurrent symptomatic paroxysmal AF despite ≥1 antiarrhythmic → ablation referral.
— New AF with reduced EF for early rhythm control consideration.
— Suspected tachycardia-mediated cardiomyopathy.
— WPW + AF — EP for ablation of accessory pathway.
— Candidates for LAAO (Watchman) — interventional cardiology/EP.
— Ensure anticoagulation prescription filled before discharge, follow-up within 1–2 weeks, and explicit communication of CHA₂DS₂-VASc and bleeding risk in discharge summary.
CCS pearl: On a CCS case of new AF with RVR and acute HF, your order set should include IV diltiazem or metoprolol, IV furosemide, supplemental oxygen titrated to saturation, TSH, troponin, BNP, echo, anticoagulation initiation (heparin → DOAC bridge), and cardiology consult — neglecting any of these will lower your score.
— Organized atrial activity at 250–350 bpm; classic sawtooth flutter waves in inferior leads (II, III, aVF).
— Often 2:1 conduction → ventricular rate ~150 bpm, regular (vs irregular in AF).
— Same thromboembolic risk as AF — apply CHA₂DS₂-VASc identically.
— Cavotricuspid isthmus ablation is highly effective (>95% success) for typical (counterclockwise) flutter — often preferred over chronic medical therapy.
— ≥3 distinct P-wave morphologies with varying PR intervals; irregularly irregular and easily mistaken for AF.
— Strongly associated with severe COPD, hypoxia, theophylline toxicity, hypomagnesemia.
— Treatment: treat underlying lung disease, replete magnesium and potassium; avoid beta-blockers in severe COPD/asthma — use non-dihydropyridine CCBs (verapamil/diltiazem).
— Single ectopic atrial focus, abnormal but consistent P-wave morphology, regular rhythm.
— Can mimic AF if rate is high; ECG shows uniform P waves.
— Sudden onset/offset, regular narrow-complex tachycardia at 150–250 bpm, often no visible P waves (buried in QRS or just after).
— Responds to vagal maneuvers and adenosine.
— Can superficially look irregular but underlying rhythm is sinus; P waves are present.
— Treat the cause (pain, fever, hypovolemia, anemia, anxiety, PE).
Key distinction: AF vs MAT vs sinus + PACs — all three are irregularly irregular. The discriminator is the P wave: absent in AF, multifocal (≥3 morphologies) in MAT, normal sinus P interrupted by ectopic P in PACs. Misdiagnosing MAT as AF and giving anticoagulation/beta-blockers is a high-yield error.
— Non-sustained VT, PVCs in bigeminy/trigeminy — palpitations and pulse irregularity; ECG shows wide complexes.
— Polymorphic VT/torsades de pointes — long QT, hypomagnesemia, drug-induced (Class IA/III antiarrhythmics, methadone, fluoroquinolones, macrolides, ondansetron).
— Second-degree AV block (Mobitz I/II) with variable conduction creates an irregular pulse but with organized atrial activity (P waves present).
— Sick sinus syndrome (tachy-brady) — alternating bradyarrhythmia and AF; often requires pacemaker before initiating rate-controlling drugs.
— Hyperthyroidism, pheochromocytoma, anxiety/panic disorder, hypoglycemia, anemia, fever, dehydration.
— Stimulant use: cocaine, methamphetamine, MDMA, caffeine excess, decongestants (pseudoephedrine), thyroid hormone misuse, energy drinks.
— Often presents with sinus tachycardia but can precipitate AF; consider in the right clinical setting (recent immobilization, malignancy, surgery, hypoxia, pleuritic chest pain).
— Can trigger AF; look for pleuritic chest pain, diffuse ST elevation with PR depression, friction rub.
— Hypokalemia, hypomagnesemia, hypocalcemia — predispose to all arrhythmias; always check and replete.
Board pearl: A post-op patient on day 2–3 with new AF — classic Step 3 scenario. Most cases (post-CABG, thoracic surgery) resolve with beta-blockade, electrolyte repletion, and treatment of precipitants within 6–8 weeks; anticoagulation decisions still follow CHA₂DS₂-VASc, and many require at least short-term anticoagulation given postoperative risk.
— DOACs preferred over warfarin for non-valvular AF (apixaban, rivaroxaban, edoxaban, dabigatran).
— Warfarin (INR 2–3) mandatory in:
— Moderate-to-severe mitral stenosis (rheumatic).
— Mechanical heart valve.
— These are the two situations where DOACs are contraindicated — RE-ALIGN trial showed harm with dabigatran in mechanical valves.
— Bioprosthetic valves and valve repair: DOACs acceptable >3 months post-op.
— Continue beta-blocker or CCB for chronic rate control.
— Maintenance antiarrhythmic if rhythm-control strategy adopted.
— Plan for repeat ablation if symptomatic recurrence after first PVI.
— Weight loss ≥10% in obese patients reduces AF burden (LEGACY trial).
— OSA treatment with CPAP — improves rhythm control and ablation success.
— Blood pressure control (<130/80).
— Alcohol reduction — abstinence reduces AF recurrence (substudy of randomized trial).
— Diabetes control, lipid management, smoking cessation, exercise.
— Anticoagulant with correct renal/weight-adjusted dose.
— Rate or rhythm agent.
— Address comorbidities (statin if indicated, ACEi/ARB for HTN/HF, SGLT2i if HFrEF or diabetes).
— Avoid drug-drug interactions: amiodarone × warfarin (boost warfarin effect — reduce INR target dose), amiodarone × digoxin (digoxin toxicity), strong CYP3A4 inhibitors with DOACs.
Step 3 management: Before discharge for new AF, ensure these five items are addressed and documented: (1) anticoagulation decision per CHA₂DS₂-VASc, (2) rate/rhythm strategy chosen, (3) reversible cause treatment, (4) follow-up appointment in 1–2 weeks, (5) patient education on symptoms requiring return.
— 1–2 weeks post-discharge or new diagnosis: assess symptom control, medication tolerance, anticoagulation adherence, BP, HR.
— 4–6 weeks post-cardioversion: ECG and clinical assessment for rhythm maintenance.
— Every 3 months in first year of new antiarrhythmic, then every 6 months.
— Annually thereafter for stable patients on chronic therapy.
— Warfarin: INR weekly until therapeutic, then every 2–4 weeks; target time-in-therapeutic-range >70%.
— DOACs: annual CBC, BMP, LFTs; more frequently in CKD (every 6 months if CrCl 30–60, every 3 months if CrCl <30). Reassess dose with weight change, age, or new interacting drugs.
— Amiodarone: TSH and LFTs q6 months; CXR and PFTs annually or on symptom; eye exam annually.
— Sotalol/dofetilide: ECG for QTc with every dose change or new interacting drug; renal function regularly.
— Flecainide/propafenone: stress test or echo periodically to ensure no new structural disease.
— Resting HR + ambulatory monitor (24-h average <100 bpm) or 6-minute walk to ensure exertional control.
— Recognize stroke symptoms — FAST mnemonic, call 911.
— Bleeding precautions — soft toothbrush, electric razor, avoid contact sports, report falls.
— Medication adherence is critical — DOACs have short half-lives; missed doses leave the patient unprotected within 24 hours.
— Drug-food-drug interactions: consistent vitamin K intake with warfarin; avoid grapefruit and strong CYP inhibitors with apixaban/rivaroxaban.
CCS pearl: Scheduling follow-up within 2 weeks of any new AF diagnosis or hospitalization is a high-yield CCS action — late follow-up (4+ weeks) is downgraded. Also order the first labs at follow-up (CBC, BMP, INR if on warfarin) at this visit.
— Anticoagulation in AF is the canonical Step 3 shared decision-making scenario. Document discussion of stroke risk (CHA₂DS₂-VASc), bleeding risk (HAS-BLED), patient values, fall risk, and willingness to accept bleeding for stroke prevention.
— A competent patient may decline anticoagulation after informed discussion — document the conversation, the absolute risks discussed, and the plan for reassessment.
— Required when patients refuse anticoagulation in the context of cognitive impairment or after embolic stroke with altered mentation.
— Use a structured assessment (understanding, appreciation, reasoning, expressing a choice).
— Surrogate decision-making invoked if the patient lacks capacity — follow advance directive or designated surrogate hierarchy.
— Anticoagulant errors at discharge are among the most common preventable harms in cardiology readmissions.
— Medication reconciliation is mandatory; explicitly stop any held bridging heparin, confirm DOAC renal dosing, communicate to the receiving PCP, and ensure the patient leaves with the prescription in hand.
— Post-syncope from AF or new antiarrhythmic initiation may warrant temporary driving restriction until rhythm and symptoms stabilize (typically 1–6 months depending on jurisdiction and commercial vs personal driving).
— Commercial pilots and drivers have stricter regulatory requirements — physicians may have mandatory reporting obligations in some states (varies; know your state's requirements).
— Avoid drug-drug interactions; deprescribe contributing agents (decongestants, NSAIDs that worsen bleeding risk and HTN, certain herbal supplements like ginkgo, St. John's Wort with warfarin).
Board pearl: The single most preventable AF complication is stroke in a patient who was eligible for anticoagulation but not prescribed it. On Step 3, any "missed opportunity" vignette (e.g., AF diagnosed but no anticoagulation initiated → subsequent stroke) is testing this exact safety gap.
— Pulmonary disease (COPD, PE), Ischemia, Rheumatic/valvular (mitral stenosis), Anemia/Atrial myxoma, Thyrotoxicosis, Ethanol/Elevated BP, Sepsis/Sleep apnea.
— AFFIRM (2002): rate vs rhythm — no mortality difference in older population → rate control acceptable.
— RACE II (2010): lenient (<110) vs strict (<80) rate control — equivalent outcomes → lenient acceptable in asymptomatic patients.
— CASTLE-AF (2018): ablation in HFrEF + AF reduces mortality and HF hospitalization.
— EAST-AFNET 4 (2020): early rhythm control within 1 year improves CV outcomes.
— CABANA (2019): ablation improves QoL and reduces recurrence.
— LEGACY (2015): weight loss ≥10% reduces AF burden.
— RE-LY, ARISTOTLE, ROCKET-AF, ENGAGE-AF: DOAC non-inferiority/superiority trials vs warfarin.
— Lenient: resting HR <110 — asymptomatic, preserved EF.
— Strict: resting HR <80 — symptomatic or HF.
— Apixaban has the lowest GI bleeding risk among DOACs.
— Dabigatran has reversible agent idarucizumab.
— Andexanet alfa reverses factor Xa inhibitors (apixaban, rivaroxaban).
— Mechanical valves and rheumatic mitral stenosis = warfarin only.
— Absent P waves + irregularly irregular = AF.
— Sawtooth + regular at 150 = flutter with 2:1 block.
— ≥3 P-wave morphologies = MAT (think COPD).
— Wide irregular at ~300 = AF with WPW (avoid AV nodal blockers).
— Avoid flecainide/propafenone in CAD/structural disease.
— Avoid dronedarone in NYHA III–IV HF.
— Avoid diltiazem/verapamil in HFrEF.
Key distinction: Valvular vs non-valvular AF for anticoagulation choice — "valvular" in this context means mechanical valve or moderate-to-severe rheumatic mitral stenosis only (mandates warfarin). All other valvular pathology (MR, AS, AR, bioprosthetic) is non-valvular for AF purposes — DOACs are appropriate.
— 72M with AF, BP 78/40, altered, crackles → synchronized DC cardioversion immediately, not adenosine, not amiodarone, not rate control.
— 65F, palpitations × 1 week, stable → rate control + anticoagulation; if elective cardioversion desired, either ≥3 weeks anticoagulation OR TEE-guided.
— 80F, AF, Cr 1.7, weight 55 kg → apixaban 2.5 mg BID (meets 2 of 3 dose-reduction criteria).
— Mechanical mitral valve + AF → warfarin (INR 2.5–3.5), not a DOAC.
— Rheumatic mitral stenosis + AF → warfarin.
— Wide irregular tachycardia at 280 bpm with varying QRS → procainamide or DCCV; avoid adenosine/beta-blocker/CCB/digoxin.
— AF + CAD post-MI → sotalol or amiodarone, not flecainide.
— AF + HFrEF → amiodarone or dofetilide, not dronedarone or flecainide.
— AF + structurally normal heart → flecainide or propafenone (with AV nodal blocker if pill-in-pocket).
— 55M, new AF, EF 30%, symptomatic → early rhythm control + ablation referral (CASTLE-AF, EAST-AFNET 4).
— 75F, AF, asymptomatic, EF 55% → rate control + anticoagulation.
— Successful cardioversion → anticoagulation × ≥4 weeks regardless of CHA₂DS₂-VASc; long-term anticoagulation per score.
— AF + weight loss + tremor + tachycardia → check TSH; treat hyperthyroidism, AF often resolves.
— AF post-binge drinking → holiday heart; supportive care + electrolyte repletion, screen for alcohol use disorder.
— Confirm with 12-lead ECG before initiating any therapy; apply CHA₂DS₂-VASc.
— Major GI bleed on apixaban → hold, resuscitate, andexanet alfa if life-threatening; reassess anticoagulation decision after stabilization, consider Watchman LAAO.
Step 3 management: When stems present multiple correct-looking interventions, ask which is the next best step right now vs which is the disposition or chronic plan — Step 3 reliably rewards the most immediately appropriate action.
In atrial fibrillation, stratify stroke risk with CHA₂DS₂-VASc and treat with anticoagulation independent of strategy, then choose rate control for older/asymptomatic patients and rhythm control (including early ablation) for younger, highly symptomatic, or HFrEF patients — always cardiovert unstable patients immediately and never give AV nodal blockers in AF with WPW.
Board pearl: Memorize the three parallel decisions in every AF patient — anticoagulation, rate vs rhythm, and reversible cause treatment — and apply them in that order; this single framework correctly handles the majority of Step 3 AF vignettes.